Previous studies have shown that immune evasion is a hallmark of cancer, and the modulation of immune responses by tumor cells can significantly impact patient prognosis.[42,43] Therefore, understanding the interplay between ACTR3 expression and immune cell dynamics could inform the development of immunotherapeutic strategies aimed at enhancing antitumor immunity in CESC patients. The gene discussed is ACTR3; the disease is cancer.